Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Trial end date:
2016-09-15
Target enrollment:
Participant gender:
Summary
This study is designed to support the optimal use of secukinumab by providing data to refine
guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to
explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients
who had less than almost clear skin at week 16.